Clinical trial / 2004
Oral NADH supplementation for 6 months prevented cognitive decline and improved total MDRS scores in patients with Alzheimer's disease.
A 6-month randomized, double-blind, matched-pairs trial evaluated 10 mg/day of stabilized oral NADH versus placebo in 26 patients with probable Alzheimer's disease. After 6 months, patients taking NADH showed no evidence of progressive cognitive deterioration and achieved significantly higher total scores on the MDRS compared with placebo (p < 0.05). Subscale analysis showed significantly better performance with NADH in verbal fluency (p = 0.019) and visual-constructional ability (p = 0.038), with a trend in abstract verbal reasoning (p = 0.08). No differences were found between groups for attention, memory, or Clinical Dementia Rating scores.
- Study type
- Randomized, placebo-controlled, matched-pairs, double-blind trial
- Who was studied
- 26 patients with probable Alzheimer's disease (12 matched pairs evaluated)
- What was measured
- Cognitive functioning measured by Mattis Dementia Rating Scale (MDRS) and subscales
THE PAPER
Treatment of Alzheimer's disease with stabilized oral nicotinamide adenine dinucleotide: a randomized, double-blind study.
Demarin V, Podobnik SS, Storga-Tomic D, Kay G. Drugs Exp Clin Res, 2004.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.